Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-134774

Published: 2020

Journal Articles

Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles

Seth E. Karol, MD, Henrique Bittencourt, MD PhD, Daniel A. Morgenstern, MD, Margaret E. Macy, MD, Seong Lin Khaw, MD, Todd M. Cooper, DO, Arnaud Petit, MD PhD, Giridharan Ramsingh, MD, Bo Tong, PhD, Kristina Unnebrink, PhD, Deeksha Vishwamitra, PhD, Fengjiao Dunbar, PhD, Betty A. Prine, BS, Tammy L. Palenski, PhD, Andrew E. Place, MDPhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136999

Published: 2020

Journal Articles

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Blood (2019) 134 (Supplement_1): 1393.

https://doi.org/10.1182/blood-2019-125257

Published: 2019

Journal Articles

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Hélène Deutsch, MD, Andre Baruchel, Joelle Guilhot, PhD, Arnaud Petit, MD PhD, Thierry Leblanc, MD, Yves Bertrand, MD, Brigitte Nelken, MD, Catherine Paillard, MD PhD, Cécile Verite, MD, Yves Réguerre, MD, Francoise Mechinaud, MD FRACP, Francois Guilhot, MD, Frederic Millot

Blood (2019) 134 (Supplement_1): 4147.

https://doi.org/10.1182/blood-2019-124060

Published: 2019

Journal Articles

Molecular Profiling Defines Distinct Prognostic Subgroups in Chilhood Acute Myeloid Leukemia: A Report from the French ELAM02 Study Group

Blood (2017) 130 (Supplement 1): 403.

https://doi.org/10.1182/blood.V130.Suppl_1.403.403

Published: 2017

Journal Articles

Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Raphael Itzykson, MD PhD, Nicolas Duployez, PharmD, PhD, Annette Fasan, PhD, Alice Marceau-Renaut, PharmD, Manja Meggendorfer, PhD, Eric Jourdan, MD, Arnaud Petit, MD PhD, Hélène Lapillonne, MD PhD, Jean-Baptiste Micol, MD PhD, Pascale Cornillet-Lefebvre, Norbert Ifrah, MD, Guy Leverger, MD PhD, Herve Dombret, MD, Nicolas Boissel, MD PhD, Torsten Haferlach, MD, Claude Preudhomme, PharmD, PhD

Blood (2017) 130 (Supplement 1): 26.

https://doi.org/10.1182/blood.V130.Suppl_1.26.26

Published: 2017

Journal Articles

Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial

Blood (2016) 128 (22): 1676.

https://doi.org/10.1182/blood.V128.22.1676.1676

Published: 2016

Journal Articles

Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines

Arnaud Petit, MD PhD, Amélie Trinquand, MD, Sylvie Chevret, MD PhD, Paola Fabiola Ballerini, MD PhD, Jean-Michel Cayuela, MD, Nathalie Grardel, MD, Aurore Touzart, MD, Benoit Brethon, MD, Hélène Lapillonne, MD PhD, Pascal Chastagner, MD, Claire Berger, MD, Gerard Michel, MD, Claude Preudhomme, MD PhD, Jean Soulier, MD PhD, Judith Landman-Parker, MD, Guy Leverger, MD, Elizabeth Macintyre, MD PhD, Andre Baruchel, MD PhD, Vahid Asnafi, MD PhD

Blood (2016) 128 (22): 1083.

https://doi.org/10.1182/blood.V128.22.1083.1083

Published: 2016

Journal Articles

Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers

Anne-Flore Derache, MD, Fanny Rialland, MD, Gerard Michel, MD, Yves Perel, MD, Virginie Gandemer, MD PhD, Pascale Blouin, MD, Odile Minckes, MD, Arnaud Petit, MD PhD, Andre Baruchel, MD PhD, Benoit Brethon, MD

Blood (2016) 128 (22): 5190.

https://doi.org/10.1182/blood.V128.22.5190.5190

Published: 2016

Journal Articles

ETO2-GLIS2 Controls Differentiation Arrest and Self-Renewal through Aberrant Enhancers Regulation in Pediatric Leukemia

Blood (2016) 128 (22): 572.

https://doi.org/10.1182/blood.V128.22.572.572

Published: 2016

Journal Articles

Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis

Blood (2014) 124 (21): 1007.

https://doi.org/10.1182/blood.V124.21.1007.1007

Published: 2014

Journal Articles

Relevance of a One-Year Maintenance Therapy with Interleukin-2 in the Treatment of Childhood Acute Myeloid Leukemia: Results from the French Multicenter, Phase III, Randomized Controlled Sfce Trial, ELAM02

Arnaud Petit, MD PhD, Stéphane Ducassou, MD, Thierry Leblanc, MD, Marlène Pasquet, MD, Alexandra Rousseau, Christine Ragu, PhD, Marine Cachanado, Brigitte Nelken, MD, Yves Bertrand, Gérard Michel, MD, Virginie Gandemer, Wendy Cuccuini, MD, Nicole Dastugue, MD, Odile Fenneteau, MD, Hélène Lapillonne, MD PhD, Anne Auvrignon, MD, André Baruchel, MD, Guy Leverger, MD

Blood (2014) 124 (21): 378.

https://doi.org/10.1182/blood.V124.21.378.378

Published: 2014

Journal Articles

Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T- Cell Acute Lymphoblastic Leukemia

Benoit Brethon, MD, Laetitia Morel, MD, Arnaud Petit, MD PhD, Etienne Lengliné, MD, Aurelie Cuinet, MD, Genevieve Vaudre, Thierry Leblanc, MD, Marie-Dominique Tabone, MD, Guy Leverger, MD, Nicolas Boissel, MD PhD, André Baruchel, MD

Blood (2014) 124 (21): 3723.

https://doi.org/10.1182/blood.V124.21.3723.3723

Published: 2014

Journal Articles

Modeling Growth Of Pediatric T-ALL In Vivo and In Vitro : Clinical Meaning and Activation Of The NFkB Pathway

Sandrine Poglio, PhD, Xavier Cahu, MD, Benjamin Uzan, PhD, Hélène Lapillonne, MD, Thierry Leblanc, MD, André Baruchel, MD, Judith Landman-Parker, MD, PhD, Arnaud Petit, MD, Frederic Baleydier, MD, PhD, Sophie Amsellem, PhD, Paola Ballerini, MD, PhD, Françoise Pflumio, PhD

Blood (2013) 122 (21): 2571.

https://doi.org/10.1182/blood.V122.21.2571.2571

Published: 2013

Journal Articles

Imatinib Has a Negative Impact On Growth In Children With Previously Untreated Chronic Myeloid Leukaemia (CML) In Early Chronic Phase (CP): Results Of The French National Study

Frédéric Millot, Joelle Guilhot, Ph.D., Andre Baruchel, MD, PhD, Arnaud Petit, MD, Thierry Leblanc, MD, Yves Bertrand, Françoise Mazingue, Patrick Lutz, Cécile Vérité, Christian Berthou, Claire Galambrun, Nicolas Sirvent, Karima Yacouben, Pascal Chastagner, Virginie Gandemer, MD, PhD, Yves Reguerre, Gérard Couillaud, Jean-Michel Cayuela

Blood (2013) 122 (21): 4001.

https://doi.org/10.1182/blood.V122.21.4001.4001

Published: 2013

Journal Articles

Molecular Responses At 3 Months Are Associated With a Better Subsequent Molecular response and Outcome In Children and Adolescents With CML In Chronic Phase: Results Of a Retrospective Analysis From The French Glivec Phase 4 Study

Frédéric Millot, Joelle Guilhot, PhD, André Baruchel, MD, Arnaud Petit, MD, Thierry Leblanc, MD, Yves Bertrand, Françoise Mazingue, Patrick Lutz, Cécile Vérité, MD, Christian Berthou, MD, Claire Galambrun, MD, Nicolas Sirvent, Karima Yacouben, Pascal Chastagner, Virginie Gandemer, MD, PhD, Yves Reguerre, MD, Gérard Couillaud, MD, Jean-Michel Cayuela

Blood (2013) 122 (21): 2730.

https://doi.org/10.1182/blood.V122.21.2730.2730

Published: 2013

Journal Articles

Excellent Prognosis of Children with ETV6-RUNX1 Positive (+) Acute Lymphoblastic Leukemia (ALL) in the FRALLE 2000 Protocol.

Virginie Gandemer, MD, Marie-Françoise Auclerc, MD, Arnaud Petit, MD, Benoît Brethon, MD, Paola Ballerini, Gerard Michel, MD, PhD, Yves Perel, MD, PhD, Anne Auvrignon, MD, Francoise Mechinaud, Claudine Schmitt, Pascale Schneider, Christiane Vermylen, Odile Lejars, MD, Thierry Leblanc, MD, Jean Gabert, MD, PhD, Elizabeth Macintyre, MD, PhD, Jean-Michel Cayuela, PharmD, PhD, Guy Leverger, MD, Andre Baruchel, MD

Blood (2009) 114 (22): 1628.

https://doi.org/10.1182/blood.V114.22.1628.1628

Published: 2009

Journal Articles

Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

Frédéric Millot, MD, Andre Baruchel, MD, Joelle Guilhot, BS, Arnaud Petit, MD, Thierry Leblanc, MD, Yves Bertrand, MD, Françoise Mazingue, Lutz Patrick, MD, Cécile Vérité, MD, Christian Berthoux, MD, Claire Galambrun, MD, Frédéric Bernard, MD, Karima Yacouben, MD, Pierre Bordigoni, Pr, Christine Edan, MD, Yves Reguerre, MD, Gérard Couillaud, MD, Jean-Michel Cayuela, MD, François Guilhot, MD

Blood (2009) 114 (22): 863.

https://doi.org/10.1182/blood.V114.22.863.863

Published: 2009

NARROW

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Venetoclax Alone or in Combination with Chemotherapy: Responses in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia with Heterogeneous Genomic Profiles

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Molecular Profiling Defines Distinct Prognostic Subgroups in Chilhood Acute Myeloid Leukemia: A Report from the French ELAM02 Study Group

Clonal Interference of Signaling Mutations Holds Prognostic Relevance in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Genomic Landscape and Prognosis in Pediatric Acute Myeloid Leukemia: A Study on the French ELAM02 Trial

Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines

Safety and Efficacy of Blinatumomab Used in Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Treated in French Hematological Centers

ETO2-GLIS2 Controls Differentiation Arrest and Self-Renewal through Aberrant Enhancers Regulation in Pediatric Leukemia

Genomic Landscape of Pediatric CBF-AML By SNP-Array Karyotyping and Extensive Mutational Analysis

Relevance of a One-Year Maintenance Therapy with Interleukin-2 in the Treatment of Childhood Acute Myeloid Leukemia: Results from the French Multicenter, Phase III, Randomized Controlled Sfce Trial, ELAM02

Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T- Cell Acute Lymphoblastic Leukemia

Modeling Growth Of Pediatric T-ALL In Vivo and In Vitro : Clinical Meaning and Activation Of The NFkB Pathway

Imatinib Has a Negative Impact On Growth In Children With Previously Untreated Chronic Myeloid Leukaemia (CML) In Early Chronic Phase (CP): Results Of The French National Study

Molecular Responses At 3 Months Are Associated With a Better Subsequent Molecular response and Outcome In Children and Adolescents With CML In Chronic Phase: Results Of a Retrospective Analysis From The French Glivec Phase 4 Study

Excellent Prognosis of Children with ETV6-RUNX1 Positive (+) Acute Lymphoblastic Leukemia (ALL) in the FRALLE 2000 Protocol.

Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only